• The Evolving Landscape of Heart Failure Therapies Neeta Ratanghayra
    January 31, 2024
    Heart failure (HF) is a leading cause of disability worldwide and has a major impact on the global economy and healthcare systems.
  • What's happening in HF therapies Neeta Ratanghayra
    January 02, 2024
    Heart failure (HF) is a leading cause of disability worldwide and has a major impact on the global economy and healthcare systems.The severity of the disease warrants the development of innovative solutions to address the current treatment gap.
  • Antibody-Drug Conjugates - Lessons Learned Neeta Ratanghayra
    May 20, 2022
    Antibody-drug conjugates (ADCs) have made significant progress in tumor therapy and show a promising future.
  • Trends and Developments in HIV Research Neeta Ratanghayra
    March 30, 2022
    Novel treatment strategies and advances in care have transformed the lives of people living with HIV (human immunodeficiency virus). Antiretroviral therapy (ART), once-daily single-tablet regimens (STRs)...
  • Bispecific Antibodies – Key Developments in China Neeta Ratanghayra
    August 06, 2021
    Bispecific antibodies (BsAbs) are artificially designed antibodies with dual binding sites. The binding sites may be directed at two different antigens or two different epitopes on the same antigen.
  • Alzheimer’s Disease - Recent Advances in Treatment Neeta Ratanghayra
    August 06, 2021
    Alzheimer's disease (AD) is a neurodegenerative disease affecting millions of people globally.
  • Antibody-Drug Conjugates – Understanding the "Trojan Horses" Neeta Ratanghayra
    May 31, 2021
    A robust strategy for targeted therapy, known as antibody-drug conjugates (ADCs), has been developed to counterfeit this challenge.
  • KRAS - Hot Cancer Target Inhibitors in Developing Neeta Ratanghayra
    March 22, 2021
    Mutant oncogenes play a key role in driving cancer progression, and this fact has set the stage for the discovery of targeted anticancer therapies.
  • Biosimilars 2020: Low Approvals, but Significant Advances Neeta Ratanghayra
    March 18, 2021
    2020 has been a tough year. The pandemic posed an array of challenges to the healthcare system and the global biopharmaceutical industry both rose to the challenges and seized opportunities.
  • Insights Into the Oncology Landscape in China Neeta Ratanghayra
    December 24, 2020
    Significant increases in incidence rates have made cancer a high priority in China. Despite major government reforms to reduce cancer burdens, problems remain. To fulfill its agenda in cancer innovation, China is embracing new frontiers and opportunities.
PharmaSources Customer Service